New drug tested in patients with liver disease – safety first
NCT ID NCT06812780
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how the drug AZD2389 behaves in people with liver impairment compared to healthy volunteers. 35 adults took a single dose, and researchers measured drug levels in the blood to check safety and processing. The goal is to understand if liver problems change how the drug works, which helps guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD2389
What this could lead to
If successful, this study could help doctors determine the right dose of AZD2389 for patients with liver disease, making the drug safer to use.
What could go wrong
This is an early-stage study with only 35 participants. It focuses on how the body handles the drug, not on treating a disease, so it may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Chandler, Arizona, 85225, United States
-
Research Site
Rialto, California, 92377, United States
-
Research Site
Miami Lakes, Florida, 33014, United States
-
Research Site
Orlando, Florida, 32809, United States
-
Research Site
San Antonio, Texas, 78215, United States